{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:42:53Z","timestamp":1774464173969,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objective<\/jats:title>\n                    <jats:p>Doravirine is among the first\u2010line recommended treatments for people living with HIV (PLHIV) in the 2025 EACS guidelines. As opposed to tenofovir alafenamide or anti\u2010integrase, its use was not associated with weight gain in clinical trials, but limited data are currently available in real life. In this cohort study, we investigated weight variation in PLHIV switching to doravirine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort analysis was conducted in two Parisian hospitals, including all PLHIV switching to doravirine between January 2019 and September 2022. Body Mass Index (BMI) variation was calculated from 48\u2009months before to 36\u2009months after the switch.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between January 2019 and December 2022, 300 patients were included, with 220 men (73%) and 185 (62%) patients born in France. The main antiretroviral combination before the switch was TAF\/FTC\/BIC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200947, 16%), and after the switch, doravirine with TDF and 3TC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009202, 67%). Twenty\u2010eight patients (9.3%) discontinued doravirine after a median duration of 17.5\u2009months. At 12 and 24\u2009months after the switch, the median BMI variation was 0.0\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , and this variation remained unchanged regardless of the pre\u2010switch treatment. These results were less pronounced in subgroups of patients originating from sub\u2010Saharan Africa (+0.2 and\u2009+0.4\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and in women (+0.3 and 0.5\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Switching to doravirine led to a weight stabilisation, without reversal of the previously gained weight. In PLHIV at higher risk of weight gain, there was still a slight increase in BMI after the doravirine switch.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70123","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:27:38Z","timestamp":1759217258000},"page":"136-145","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact on weight of a Doravirine switch in people living with\n                    <scp>HIV<\/scp>"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3631-1828","authenticated-orcid":false,"given":"Nina","family":"Garofoli","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases Hopitaux de Paris Nord, Saint\u2010Antoine Hospital  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-3522","authenticated-orcid":false,"given":"Philippe","family":"Flandre","sequence":"additional","affiliation":[{"name":"INSERM UMR\u2010S1136 Universit\u00e9 Sorbonne Paris  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Paul","family":"Vincensini","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Hopitaux de Paris Nord, Saint\u2010Antoine Hospital  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-6405","authenticated-orcid":false,"given":"Quentin","family":"Richier","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Hopitaux de Paris Nord, Saint\u2010Antoine Hospital  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscille","family":"Couture","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Hopitaux de Paris Nord, Saint\u2010Antoine Hospital  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Hopitaux de Paris Nord, Saint\u2010Antoine Hospital  Paris France"},{"name":"INSERM UMR\u2010S1136 Universit\u00e9 Sorbonne Paris  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Pialoux","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Hopitaux de Paris, Tenon Hospital  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Luc","family":"Meynard","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Hopitaux de Paris Nord, Saint\u2010Antoine Hospital  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30241-1"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25484"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.36469\/jheor.2020.13457","article-title":"Real\u2010world assessment of weight change in people with HIV\u20101 after initiating integrase Strand transfer inhibitors or protease inhibitors","volume":"7","author":"Chen Y\u2010W","year":"2020","journal-title":"J Health Econ Outcomes Res"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz407"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101412"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07091-1"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/QAI.0b013e31827303d5","article-title":"Multimorbidity patterns in HIV\u2010infected patients: the role of obesity in chronic disease clustering","volume":"61","author":"Kim DJ","year":"2012","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hiv.12294","article-title":"Short\u2010term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:a:D study","volume":"17","author":"Achhra AC","year":"2016","journal-title":"HIV Med"},{"key":"e_1_2_10_11_1","first-page":"S27","article-title":"Causes et caract\u00e9ristiques des d\u00e9c\u00e8s chez des PVVIH suivies entre 2016 et 2020: Etude MORTIFO","volume":"1","author":"Caby F","year":"2022","journal-title":"MMI Formation"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001495"},{"key":"e_1_2_10_13_1","unstructured":"guidelines_10.0_french__1_.pdf."},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/QAI.0000000000002642","article-title":"Brief report: switching to DOR\/3TC\/TDF maintains HIV\u20101 Virologic suppression through week 144 in the DRIVE\u2010SHIFT trial","volume":"87","author":"Kumar P","year":"1999","journal-title":"J Acquir Immune Defic Syndr 2021"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy540"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30336-4"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002725"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029855"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2022.0058"},{"key":"e_1_2_10_20_1","unstructured":"Grace and McComsey.Weight and body composition after switch to doravirine\/islatravir (DOR\/ISL) 100\/0.75mg once daily: week 48 results from 2 randomized active\u2010controlled phase 3 trials MK8591A\u2010017 (P017) and MK8591A\u2010018 (P018).https:\/\/www.natap.org\/2023\/IAS\/IAS_51.htm"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/09564624231195084"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003337"},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/QAI.0000000000002879","article-title":"Brief report: efficacy and safety of Oral Islatravir once daily in combination with Doravirine through 96\u2009weeks for treatment\u2010naive adults with HIV\u20101 infection receiving initial treatment with Islatravir, Doravirine, and lamivudine","volume":"91","author":"Molina J\u2010M","year":"1999","journal-title":"J Acquir Immune Defic Syndr 2022"},{"key":"e_1_2_10_24_1","unstructured":"EACS.EACS Guidelines.2023https:\/\/eacs.sanfordguide.com\/contents\/changes-v11-0-to-v11-1"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac631"},{"key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12879-023-08071-9","article-title":"Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users","volume":"23","author":"Slama L","year":"2023","journal-title":"BMC Infect Dis"},{"key":"e_1_2_10_27_1","unstructured":"Doravirine injections were safe and long\u2010lasting but did not reach therapeutic levels. aidsmap.com.2020https:\/\/www.aidsmap.com\/news\/aug\u20102020\/doravirine\u2010injections\u2010were\u2010safe\u2010and\u2010long\u2010lasting\u2010did\u2010not\u2010reach\u2010therapeutic\u2010levels"},{"key":"e_1_2_10_28_1","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long\u2010acting cabotegravir plus rilpivirine versus continuing fixed\u2010dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12\u2010month results (SOLAR): a randomised, open\u2010label, phase 3b, non\u2010inferiority trial","volume":"10","author":"Ramgopal MN","year":"2023","journal-title":"Lancet HIV"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-023-00665-x"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","unstructured":"ShortWR.A prospective randomized trial to assess a protease inhibitor\u2013based regimen switch strategy to manage integrase inhibitor\u2013related weight gain.2023https:\/\/programme.ias2023.org\/Abstract\/Abstract\/?abstractid=5962","DOI":"10.1093\/ofid\/ofad500.112"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T10:55:47Z","timestamp":1767351347000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/hiv.70123"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70123","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"2025-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}